Tags : Patent


Coherus Biosciences Reports Winning of Pegfilgrastim Patent Dispute Against Amgen

Shots: Coherus announces the Federal Circuit affirmation decision of the US District Court for the District of Delaware appealing that Coherus’ Udenyca (biosimilar, pegfilgrastim) does not infringe Amgen’s asserted patent  On May 10, 2017 under BPCIA act, Amgen filled a patent infringement complaint against Coherus asserting US Patent 8,273,707 (“the ’707 patent”), further in response […]Read More